Share
Maurizio Ceppi
Transgene, a biotech company specializing in virus-based immunotherapies for cancer treatment, has announced the appointment of Emmanuelle Dochy, MD, as Chief Medical Officer (CMO), and Maurizio Ceppi, PhD, as Chief Scientific Officer (CSO). These appointments mark a key step in advancing the company’s innovative cancer immunotherapy programs.
Dr. Dochy succeeds Dr. Maud Brandely, MD, PhD, who is retiring, and will lead Transgene’s clinical development efforts, overseeing upcoming data readouts from the company’s portfolio. Dr. Ceppi takes over from Eric Quéméneur, PharmD, PhD, and will focus on driving scientific innovation and the development of new immunotherapies. Both Dr. Brandely and Dr. Quéméneur will work with their successors, with Dr. Brandely continuing as a consultant.
Alessandro Riva, MD, Chairman and CEO of Transgene, expressed enthusiasm for the new leadership, highlighting their expertise in oncology and contributions to advancing precision medicines. He also extended gratitude to Dr. Brandely and Dr. Quéméneur for their years of dedicated service.
